On May 2, 2025, Citigroup analyst Yigal Nochomovitz maintained his "Buy" rating for Ardelyx (ARDX, Financial), while lowering the stock's price target. The new price target has been adjusted to $10.00, down from the prior target of $11.00.
This adjustment represents a 9.09% reduction in the price target. Despite the lowered target, the "Buy" rating indicates the analyst's continued positive outlook on Ardelyx (ARDX, Financial), suggesting that the stock remains an attractive investment opportunity at its current valuation.
The price target adjustment and maintained rating reflect ongoing analysis and assessments made by Citigroup regarding Ardelyx's (ARDX, Financial) market positioning and potential future performance within the pharmaceutical industry.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 11 analysts, the average target price for Ardelyx Inc (ARDX, Financial) is $10.68 with a high estimate of $15.00 and a low estimate of $5.50. The average target implies an upside of 158.64% from the current price of $4.13. More detailed estimate data can be found on the Ardelyx Inc (ARDX) Forecast page.
Based on the consensus recommendation from 12 brokerage firms, Ardelyx Inc's (ARDX, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Ardelyx Inc (ARDX, Financial) in one year is $19.79, suggesting a upside of 379.18% from the current price of $4.13. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Ardelyx Inc (ARDX) Summary page.
